✦ LIBER ✦

Longitudinal Design for Phase I Clinical Trials Using the Continual Reassessment Method

✍ Scribed by Anna T.R Legedza; Joseph G Ibrahim

Book ID: 114186780
Publisher: Elsevier Science
Year: 2000
Tongue: English
Weight: 354 KB
Volume: 21
Category: Article
ISSN: 0197-2456
DOI: 10.1016/s0197-2456(00)00091-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adaptive design improvements in the cont

Adaptive design improvements in the continual reassessment method for phase I studies

✍ Julie M. Heyd; Bradley P. Carlin 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB 👁 2 views

The continual reassessment method (CRM) enables full and e$cient use of all data and prior information available in a phase I study. However, despite a number of recent enhancements to the method, its acceptance in actual clinical practice has been hampered by several practical di$culties. In this p

39A Incorporating toxicity grade informa

39A Incorporating toxicity grade information in the continual reassessment method for phase I cancer clinical trials

✍ Carl A. de Moor; Susan G. Hilsenbeck; Gary M. Clark 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 116 KB

A trivariate continual reassessment meth

A trivariate continual reassessment method for phase I/II trials of toxicity, efficacy, and surrogate efficacy

✍ Wei Zhong; Joseph S. Koopmeiners; Bradley P. Carlin 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB

The bivariate continual reassessment met

The bivariate continual reassessment method: extending the CRM to phase I trials of two competing outcomes

✍ Thomas M. Braun 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 148 KB

Using the continual reassessment method:

Using the continual reassessment method: Lessons Learned from an EORTC phase I dose finding study

✍ Xavier Paoletti; Benoît Baron; Patrick Schöffski; Pierre Fumoleau; Denis Lacombe 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 185 KB

Continual reassessment methods in phase

Continual reassessment methods in phase I trials of the combination of two drugs in oncology

✍ Andrew Kramar; Anne Lebecq; Emmanuel Candalh 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB 👁 2 views

Most phase I trials in oncology use standard methods for treating successive groups of patients with increasing doses in order to determine the maximum tolerated dose (MTD). These methods have been criticized because they treat many patients at suboptimal dose levels, and do not provide an accurate